Yuviclav 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg and Clavulanic Acid 125 mg. Amoxycillin, a broad-spectrum penicillin antibiotic, inhibits bacterial cell wall synthesis, leading to cell lysis and death, while Clavulanic Acid acts as a beta-lactamase inhibitor, preventing enzymatic degradation of Amoxycillin by resistant bacteria. This synergistic action extends the antimicrobial spectrum of Amoxycillin against beta-lactamase producing pathogens. Yuviclav 625 is indicated for the treatment of various bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media, sinusitis, and dental infections caused by susceptible organisms. It is effective against both gram-positive and gram-negative bacteria, including strains resistant to Amoxycillin alone. The recommended dosage and duration of therapy should be determined by a healthcare professional based on the severity and type of infection. Caution is advised in patients with a history of penicillin allergy or hypersensitivity reactions. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and vomiting. Yuviclav 625 should be used with caution in patients with hepatic or renal impairment. Proper adherence to prescribed dosage and completion of the full course of therapy is essential to prevent resistance development.